[On the effect of a cytostatic of the methylhydrazine group on malignant hemoblastomas].
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy; D006801:Humans; D006834:Hydrazines / Q000627:therapeutic use*; D007945:Leukemia, Lymphoid / Q000188:drug therapy; D007951:Leukemia, Myeloid / Q000188:drug therapy; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy; D008206:Lymphatic Diseases / Q000188:drug therapy*; D008223:Lymphoma / Q000188:drug therapy*; D008224:Lymphoma, Follicular / Q000188:drug therapy; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D008297:Male; D008545:Melanoma / Q000188:drug therapy
D000970:Antineoplastic Agents; D006834:Hydrazines
Uber die Wirkung eines Zytostatikums aus der Methylhydrazinreihe bei malignen Hämoblastosen.